Tempest Therapeutics, Inc. (TPST) is a clinical-stage biotechnology company headquartered in Brisbane, California. After a steep decline from a 52-week high near $12.23, reached in October 2025, shares had fallen to roughly $1.21 in recent trading, leaving the stock down more than 85% over the trailing year. The single widely published analyst price objective — an $11 target from H.C. Wainwright, which upgraded the stock to Buy in January 2026 — sits far above the current quote. That gap is exactly why investors ask whether TPST can reach $11 again.
Tempest has historically been known for its small-molecule oncology pipeline, led by amezalpat, an oral PPARα antagonist that completed a Phase 2 trial in hepatocellular carcinoma and is partnered with Roche for a global first-line study. More recently, the company has refocused around "in vivo" cell therapy, an approach designed to generate CAR-T and CAR-NK cells directly inside a patient's body, bypassing the costly, complex outside-the-body manufacturing used in conventional autologous CAR-T treatments.
In September 2026, Tempest announced an exclusive option agreement with China-based Hebei Senlang Biotechnology to license a CD7-targeted lentiviral vector platform. The portfolio includes a BCMA/GPRC5D dual-targeting candidate in a Phase 1 dose-escalation study for relapsed or refractory multiple myeloma. Early observations reported no Grade 3 or higher cytokine release syndrome or neurotoxicity as of August 2026. The news, paired with a $2.5 million warrant-based private placement, drove a sharp one-day rally in TPST shares.
The most direct path toward a higher share price runs through clinical catalysts. Positive early data from the BCMA/GPRC5D in vivo CAR-T program, or a decision to exercise the Senlang option, could materially change the company's perceived value. Likewise, advancement of Tempest's internal TPST-4003 candidate — a CD7-targeted lipid nanoparticle (LNP) platform planned to enter the clinic — would give investors a second, fully owned in vivo cell-therapy approach to track. In a market that rewards validated oncology platforms, successful early-stage data has historically been capable of producing outsized moves in micro-cap biotech names.
The obstacles are substantial. Tempest reported total cash of only about $0.8 million in its most recent quarter, a level that raises immediate questions about funding. A company with negative trailing-twelve-month net income near $40 million and no product revenue must raise capital, and equity or warrant financings typically dilute existing shareholders. The $2.5 million private placement announced alongside the Senlang agreement underscores how small and recurring these capital infusions are relative to the company's burn rate.
Tempest has also been flagged as failing to meet Nasdaq's continued listing requirements, a status that can lead to reverse stock splits or delisting proceedings if not resolved. Even if a reverse split boosts the nominal share price, it does not change the underlying market capitalization. These structural risks sit squarely between the current quote and any meaningful recovery toward $11.
Coverage of TPST is thin, with effectively a single published 12-month target of $11. That figure reflects a highly speculative, event-driven view rather than a broad consensus, and analyst targets on clinical-stage biotechs can be revised dramatically as data and funding evolve. At a market capitalization near $20 million and no current revenue, traditional valuation metrics such as the P/E ratio (price-to-earnings) are not meaningful. The stock's value is almost entirely tied to the probability-weighted potential of its pipeline.
From a technical standpoint, the 52-week low near $0.74 is the critical support level that bulls must hold to avoid fresh lows. The psychological $1.00 level has also been a focal point after the recent spike. On the upside, the prior 52-week high near $12.23 represents the recovery ceiling, and $11 sits just beneath it. Because the stock has traded through such an extreme range in the past year, its technical structure is dominated by wide, volatile swings rather than stable, well-defined trend lines.
Traders tracking volatile names like TPST can use AI Daily Buy/Sell Signals to monitor shifting conditions more efficiently. The product applies artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market behavior, technical patterns, and AI-driven analysis. These signals are designed to help traders spot emerging opportunities, keep an eye on existing positions, and identify changing trends without manually reviewing every chart. For investors seeking a data-driven way to complement their own research, the platform offers a practical starting point.
Reaching $11 from a recent price near $1.21 would require an extraordinary, roughly nine-fold move. While that target is not unprecedented — the stock traded above $12 within the last year — it is far from a base case. The bullish case rests on successful execution of the in vivo CAR-T strategy and positive early clinical data, which could re-rate the entire pipeline. The bear case centers on an extremely thin cash position, ongoing dilution, and a Nasdaq listing deficiency. Investors should monitor upcoming clinical readouts, financing announcements, and any resolution of the listing status, recognizing that this remains a high-risk, catalyst-dependent situation.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TPST has been loosely correlated with TYRA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if TPST jumps, then TYRA could also see price increases.
| Ticker / NAME | Correlation To TPST | 1D Price Change % | ||
|---|---|---|---|---|
| TPST | 100% | +0.50% | ||
| TYRA - TPST | 41% Loosely correlated | +0.74% | ||
| AGIO - TPST | 41% Loosely correlated | +0.22% | ||
| NRIX - TPST | 40% Loosely correlated | +0.58% | ||
| PVLA - TPST | 36% Loosely correlated | +2.02% | ||
| KRRO - TPST | 33% Loosely correlated | +7.48% | ||
More | ||||